Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 1.00 |
| ▸ | SYNJ2 | O15056 | 1/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | SYNJ1 | O43426 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | MAOA | P21397 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | NPY1R | P25929 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 1/20 | 1.00 |
| ▸ | BDKRB2 | P30411 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrvinium SCHEMBL30383133 | 1.00 | AR (1.00) | ARSYNJ2MLNRSYNJ1PGR | |
| Pyrvinium SCHEMBL149062 | 1.00 | AR (1.00) | ARSYNJ2MLNRSYNJ1PGR | |
| Pyrvinium SCHEMBL16291465 | 1.00 | AR (1.00) | ARSYNJ2MLNRSYNJ1PGR | |
| Pyrvinium SCHEMBL30642307 | 1.00 | AR (1.00) | ARSYNJ2MLNRSYNJ1PGR | |
| Pyrvinium SCHEMBL29387513 | 1.00 | AR (1.00) | ARSYNJ2MLNRSYNJ1PGR | |
| Pyrvinium SCHEMBL21111996 | 0.99 | AR (0.98) | ARSYNJ2MLNRSYNJ1PGR | |
| Pyrvinium SCHEMBL646420 | 0.99 | AR (0.98) | ARSYNJ2MLNRSYNJ1PGR | |
| Pyrvinium SCHEMBL646419 | 0.99 | AR (0.98) | ARSYNJ2MLNRSYNJ1PGR | |
| Pyrvinium SCHEMBL4877919 | 0.94 | AR (0.89) | ARSYNJ2MLNRSYNJ1PGR | |
| Pyrvinium SCHEMBL4881741 | 0.94 | AR (0.89) | ARSYNJ2MLNRSYNJ1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1093 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122024819-A | Method for screening atopic dermatitis key autophagy genes based on transcriptome and machine learning | 常德市第一人民医院 | 2026-05-12 | — | — | CN | claimed |
| US-20260108480-A1 | METHODS FOR INDUCING PROLIFERATION OF STEM CELLS | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2026-04-23 | — | — | US | claimed |
| US-20260076969-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-03-19 | — | — | US | claimed |
| US-12570956-B2 | Efficient derivation of stable pluripotent bovine embryonic stem cells | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-03-10 | — | — | US | claimed |
| WO-2025264721-A1 | ENHANCEMENT OF REGENERATIVE ACTIVITY BY INACTIVATION OF SENESCENT CELLS | IMMORTA BIO, INC. (US) | 2025-12-26 | — | — | WO | claimed |
| US-12447147-B2 | Methods of treating, ameliorating, and/or preventing cancer using pyrvinium compositions | THOMAS JEFFERSON UNIVERSITY (US) | 2025-10-21 | — | — | US | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| EP-3976197-B1 | THERAPEUTICS AND METHODS FOR PREDICTING AND OVERCOMING ENDOCRINE RESISTANCE IN BREAST CANCER | LUNELLA BIOTECH INC (CA) | 2025-07-16 | — | — | EP | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-12295957-B2 | Ascorbic acid and quinone compounds in combination with an antiparasitic agent for treating a parasitic disease | IC-MedTech Corp. (US) | 2025-05-13 | — | — | US | claimed |
| WO-2008150845-A1 | SCREENING FOR WNT PATHWAY MODULATORS AND PYRVINIUM FOR THE TREATMENT OF CANCE | VANDERBILT UNIVERSITY (US) | 2008-12-11 | — | — | WO | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| EP-1883452-A2 | PHARMACEUTICAL COMPOSITION CONTAINING AN ANTI PARASITIC AGENT AND AN ACTIVE INGREDIENT SELECTED FROM CARVEOL, THYMOL, EUGENOL, BORNEOL, CARVACROL, ALPHA-IONONE, OR BETA-IONONE | ASD (Advanced Scientific Developments) (MA) | 2008-02-06 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| WO-2006120568-A2 | PHARMACEUTICAL COMPOSITION CONTAINING AN ANTI PARASITIC AGENT AND AN ACTIVE INGREDIENT SELECTED FROM CARVEOL, THYMOL, EUGENOL, BORNEOL, CARVACROL, ALPHA-IONONE, OR BETA-IONONE | ADVANCED SCIENTIFIC DEVELOPEMENTS (MA) | 2006-11-16 | — | — | WO | claimed |
| WO-2006120495-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ANTIVIRAL AGENT, AN ANTITUMOUR AGENT OR AN ANTIPARASITIC AGENT AND AN ACTIVE SUBSTANCE SELECTED FROM CARVEOL, THYMOL, EUGENOL, BORNEOL AND CARVACROL | ADVANCED SCIENTIFIC DEVELOPEMENTS (MA) | 2006-11-16 | — | — | WO | claimed |
| US-20060252049-A1 | Growth-promoting and immunizing subcutaneous implant | IVY ANIMAL HEALTH, INC. | 2006-11-09 | — | — | US | claimed |
| EP-0507629-B1 | Sustained release capsule and formulations for insertion into rumen | LILLY CO ELI (US) | 1997-01-22 | — | — | EP | claimed |
| EP-0080341-B1 | PHARMACEUTICAL MULTIPLE-UNITS FORMULATION | A/S Alfred Benzon (DK) | 1987-10-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12447147-B2 | Methods of treating, ameliorating, and/or preventing cancer using pyrvinium compositions | RNASE1, PDXK, PNLIP | AR 1717/4885SYNJ2 4226/4885MLNR 872/4885 |
| US-20260108480-A1 | METHODS FOR INDUCING PROLIFERATION OF STEM CELLS | CYP4X1, SLC6A7, ZFX | AR 2055/4885SYNJ2 2411/4885MLNR 3960/4885 |
| US-12570956-B2 | Efficient derivation of stable pluripotent bovine embryonic stem cells | WNT1, PHKA1, ACVR1 | AR 3905/4885SYNJ2 1063/4885MLNR 2684/4885 |
| US-12295957-B2 | Ascorbic acid and quinone compounds in combination with an antiparasitic agent for treating a parasitic disease | NQO1, ADH7, CYP27B1 | AR 4427/4885SYNJ2 3303/4885MLNR 1427/4885 |
| US-20260076969-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | ATP5ME, MT-ATP6, ATP5MK | AR 3084/4885SYNJ2 3475/4885MLNR 1585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.